Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Pfizer and BioNTech test omicron-specific COVID-19 vaccine in adults

By Brian Buntz | January 25, 2022

Pfizer-BioNTechWith COVID-19 cases continuing to hover near record levels, Pfizer (NYSE:PFE) and partner BioNTech SE (NSDQ:BNTX) have launched a clinical trial to test an omicron-based vaccine candidate in adults ages 18 to 55.

The study will enroll 1,420 participants divided into three cohorts.

The first cohort will have already received two doses of the initial Pfizer-BioNTech Comirnaty vaccine for COVID-19. Members of that cohort will then receive one or two doses of the updated vaccine.

The second cohort, after already receiving three doses of the current Pfizer-BioNTech Comirnaty vaccine, will get one dose of the omicron-based vaccine.

The third cohort will include vaccine-naïve subjects, which will get three doses of the omicron-specific vaccine.

The omicron variant remains more resistant to vaccines than other SARS-CoV-2 variants of concern.

Pfizer and BioNTech hope the updated vaccine will ultimately offer more effective and longer-lasting protection against the omicron variant.

“Vaccines continue to offer strong protection against severe disease caused by omicron,” BioNTech CEO Ugur Sahin said in a press release. “Yet, emerging data indicate vaccine-induced protection against infection and mild to moderate disease wanes more rapidly than was observed with prior strains.”

Moderna (NASDAQ:MRNA) is also working on an omicron-based version of its vaccine. The company anticipates that data from the updated candidate will be ready in March.

Pfizer and BioNTech plan to produce 4 billion doses of COVID-19 vaccine this year. The two companies don’t expect the potentially updated vaccine to change that projection.

PFE shares were up 2.25% to $52.72 in afternoon trading, while BNTX shares were up 6.68% to $161.07.


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: BioNTech, coronavirus, covid-19, COVID-19 vaccine, Pfizer
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Janssen
Janssen’s company group chairman dishes on growth strategy
Curebase
Curebase raises $40 million in Series B funding round 

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50